Evaluation of Glycomic Profiling as a Diagnostic Biomarker for Epithelial Ovarian Cancer
Menée sur des échantillons sanguins prélevés sur 147 patientes atteintes d'un cancer de l'épithélium ovarien, sur 52 patientes atteintes d'une tumeur à faible potentiel malin et sur 100 témoins sains, cette étude évalue l'intérêt de mesurer l'expression de glycanes pour le diagnostic d'un cancer de l'ovaire
BACKGROUND: Prior studies suggested that glycans were differentially expressed in ovarian cancer patients and controls. We hypothesized that glycan-based biomarkers might serve as a diagnostic test for ovarian cancer and evaluated the ability of glycans to distinguish ovarian cancer cases from matched controls.
METHODS: Serum samples were obtained from the tissue-banking repository of the Gynecologic Oncology Group, and included healthy female controls (n= 100), women diagnosed with low malignant potential (LMP) tumors (n=52), and epithelial ovarian cancers (EOC) cases (n= 147). Cases and controls were matched on age at enrollment within ± 5 years. Serum samples were analyzed by glycomics analysis to detect abundance differences in glycan expression levels. A two-stage procedure was carried out for biomarker discovery and validation. Candidate classifiers of glycans that separated cases from controls were developed using a training set in the discovery phase and the classification performance of the candidate classifiers was assessed using independent test samples that were not used in discovery.
RESULTS: The patterns of glycans showed discriminatory power for distinguishing EOC and LMP cases from controls. Candidate glycan-based biomarkers developed on a training set (sensitivity = 86% and specificity = 95.8% for distinguishing EOC from controls through LOOCV) confirmed their potential use as a detection test using an independent test set (sensitivity = 70% and specificity =86.5%).
CONCLUSION: Formal investigations of glycan biomarkers that distinguish cases and controls show great promise for an ovarian cancer diagnostic test. Further validation of a glycan-based test for detection of ovarian cancer is warranted.-
Cancer Epidemiology Biomarkers & Prevention , résumé, 2014